Showing posts with label Orexigen Therapeutics. Show all posts
Showing posts with label Orexigen Therapeutics. Show all posts

Thursday, June 15, 2017

Herbalife: Profiting From The Obesity Pandemic


  • As the wrath of notable activist investors is abated, Herbalife settled with the FTC and seemingly moved on.
  • Earnings increase is expected in the foreseeable future due to brand enhancement and the absence of costly legal fees.
  • By capturing the obesity pandemic, Herbalife has much room for further growth.
  • Valuations suggest the company is a significant bargain.

Since 2012, companies operating in the personal wellness industry - Nu Skin Enterprises (NYSE:NUS) and USANA Health Sciences (NYSE:USNA) - experienced tumultuous tanking in share price, as notorious activist investors waged their battles. Slugging in the red corner is the famed bear, Bill Ackman (principal of Pershing Square). Charging in the green corner is the golden bull, Carl Icahn, of Icahn Enterprises (NYSE:IEP). With their history of personal and professional conflicts, these two titans slugged it out in the epic battles for Herbalife Ltd. (NYSE:HLF). Headquartered in the Cayman Islands, the company makes "nutrition products with protein, fiber, and vitamins to enhance and support a healthy and balanced lifestyle."

To learn more how Dr. Tran BioSci can serve your specific needs ...

If you enjoy reading our research, be sure to sign up for our mailing list at Dr. Tran BioSci to get the latest market outperforming insights.

To access the complete article, please go to the premier investing research platform Seeking Alpha.

Saturday, June 3, 2017

The 'Real Story' Behind Orexigen Therapeutics, Inc.

Editor's notes: I published a short thesis on Orexigen on Dec. 24, 2013, to warn investors of the market hype/manipulation. The article was met with strong criticism. Needless to say, those that heeded my warnings would save themselves from losing more than 95% of their invested capital. Those who shorted this whisper-stock would have enjoyed a 95% gain.


Truth be told, I have not shorted any stocks in years. According to Warren Buffett's mentor, Benjamin Graham, when shorting stocks one must have convincing evidence. In this research, I wanted to release the overwhelming evidence proving that Orexigen Therapeutics, Inc. (NASDAQ:OREX) is fundamentally unsound. Moreover, while the FDA approval decision for Contrave is still "up to the jury," Orexigen would surely face the insurmountable problem of dismal sales for Contrave should the drug ever gain marketing approval. Contrary to the prevailing notion of the market, I strongly believe that the future for Orexigen is full of calamities. Consequently, investing in this "whisper stock" would only result in imminent financial catastrophe for investors and speculators alike.